application sweet spot

Treating localized diseases such as locally-advanced solid tumors where dose-effect relation could be a game changer in treatment outcomes

Our proprietary TSL technology is ideally suited for the treatment of localized diseases. While our own drug development focuses on oncological indications, our technology can be applied in multiple indications and therapeutic areas where the used drug:

  • needs an intravenous (systemic) route of administration with the aim of treating a local disease
  • is highly toxic and thereby only allows low dosages which may not be effective enough due to dose-limiting side effects – and/or
  • is poorly accumulating in the site of action due to an intravenous (systemic) route of administration and thus results in insufficient local drug concentration to reach effective outcomes – and/or
  • can only be applied short-term due to toxic side effects, hindering an effective long-term treatment of patients (whereas a focused application might allow lower dosages at higher local drug concentration enabling a long-term treatment)

Our focus: locally-advanced solid tumors

Within oncology, the application sweet spot are so-called locally-advanced solid tumors, i.e., tumors that are mostly not yet metastatic but already relatively large and thus either not or only border-line resectable. Thus, the primary tumor is the main focus of a medical treatment with surgery as the gold standard not being possible or associated with major morbidity for the patient due to the already large size and involvement of nerves or large blood vessels.

Patients in these stages typically receive neoadjuvant radiotherapy or drug-based chemotherapy aiming to shrink the tumor preoperatively and thereby enabling tumor surgery (as surgery is a major driver in survival of cancer patients), potentially followed by adjuvant radiotherapy or chemotherapy post-operatively.

Through our Thermosomes, we can increase the local drug concentration in the primary tumor by a factor of 10-15, thereby dramatically changing the pharmaceutical quality of the encapsulated drug in threating localized tumors (dose-effect relation). In several pre-clinical proof-of-concept studies of our lead candidate (a commonly used, highly potent but toxic chemotherapeutic) in different animal species with both cell-line based grown tumors and naturally grown tumors, we have shown a dramatic improvement in efficacy in treating the primary tumor while simultaneously reducing systemic and local side effects as compared to conventional systemic drug application. Thus, we may significantly enlarge the therapeutic and safety window of these drugs and reach improved therapeutic outcomes in patients with locally-advanced solid tumors.

Ideally, a significant proportion of patients suffering from locally-advanced, not or border-line resectable solid tumors may benefit from a significant shrinkage of the tumor and be eligible for tumor surgery. The result would be curative treatment options for previously not resectable, locally-advanced solid tumors. In patients in whom the tumor will not be resectable, our technology may offer the possibility of long-term tumor control with considerably lower side effects.